EMA Recommends Extension of Indications for Sugemalimab By Ogkologos - October 28, 2025 407 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns monotherapy for the treatment of unresectable stage III NSCLC with no genomic alterations Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR EMA Recommends Granting a Marketing Authorisation for Acalabrutinib July 30, 2020 Peptide Receptor Radionuclide Therapy [177Lu]Lu-Edotreotide Prolongs PFS in Patients with Advanced,... July 28, 2026 EMA Recommends Granting a Marketing Authorisation for Zanubrutinib for the Treatment... October 21, 2021 Peer-to-peer match-funding initiative raises over £4 million for cancer research May 18, 2021 Load more HOT NEWS Baby Boy Can’t Stop Smiling After Surgery Allows Him To See... Exceptional Response to Single-Agent Anti-PD1 Therapy Observed in Patients with Advanced... FDA Approves Gemtuzumab Ozogamicin for CD33-positive AML in Paediatric Patients Adding Blinatumomab to Chemotherapy Improves DFS in Patients with Newly Diagnosed...
